Enteral Very Low-Calorie Protein Formula Investigated for Severe Obesity Management

Individuals suffering from severe obesity often require rapid and substantial weight loss interventions to improve health outcomes and prepare for further treatments. Very Low-Calorie Diets (VLCDs) are established methods for achieving significant weight reduction, but their implementation can be challenging. This clinical trial aimed to investigate the efficacy and safety of a specific, medically supervised enteral VLCD formulation for the management of severe obesity.

This clinical trial, completed in 2013, aimed to rigorously evaluate the efficacy and safety of its 2-week enteral very low-calorie protein-based formula in achieving significant weight loss and improving metabolic parameters in patients with severe obesity. While the NCT record details the comprehensive study design and the specific components of the intervention, it does not provide the actual outcome data or results from the 364 participants. The primary objective was to demonstrate a substantial reduction in body weight, which is a critical step in managing severe obesity and its associated comorbidities. The study's completion indicates that data was collected and analyzed, but specific findings such as average weight loss, changes in body composition, or improvements in blood markers are not publicly available within this registration. This record describes a completed clinical trial designed to assess the impact of a 2-week enteral very low-calorie protein-based formula on weight reduction in 364 individuals with severe obesity.